Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects Lesion(s) in Adolescent Subjects With STGD1
研究单位：[1]Belite Bio, Inc[2]Stanford Byers Eye Institute,Palo Alto,California,United States,94303[3]Vitreoretinal Associates,Gainesville,Florida,United States,32607[4]Vitreo Retional Surgery PLLC,Minneapolis,Minnesota,United States,55435[5]Columbia University Irving Medical Center, Harkness Eye Institute,New York,New York,United States,10032[6]University of Utah Health,Salt Lake City,Utah,United States,84132[7]Sydney Children's Hospitals Network,Westmead,New South Wales,Australia,2145[8]Centre For Eye Research Australia Ltd,East Melbourne,Victoria,Australia,3002[9]Queensland Eye Institute,South Brisbane,Australia,4101[10]UZ Gent,Gent,Belgium,9000[11]UZ Leuven,Leuven,Belgium,3000[12]Beijing Tongren Hospital - Capital Medical University,Beijing,China[13]Beijing Union Medical college Hospital,Beijing,China[14]Eye and ENT Hospital of Fudan University,Shanghai,China[15]Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts,Paris,France,75571[16]Universitätsklinikum Bonn,Bonn,Germany,53127[17]Justus-Liebig Universitätklinikum,Gießen,Germany,35392[18]Universitätsklinikum Tübingen,Tübingen,Germany,72076[19]Hong Kong Eye Hospital,Kowloon,Hong Kong[20]Amsterdam University Medical Centers,Amsterdam,Netherlands[21]Radboud University Medical Centers,Nijmegen,Netherlands[22]Rotterdam Ophthalmic Institute,Rotterdam,Netherlands[23]University Hospital Basel, Eye Clinic,Basel,Switzerland,4031[24]National Taiwan University Hospital,Taipei,Taiwan,10002[25]Chang Gung Memorial Hospital, Linkou,Taoyuan City,Taiwan,33305[26]Moorfields Eye Hospital,London,United Kingdom,EC1V 2PD[27]Manchester Centre for Genomic Medicine,Manchester,United Kingdom,M13 9WL[28]Southampton General Hospital,Southampton,United Kingdom,SO16 6YD
研究目的：
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
